{"id":408579,"date":"2021-01-05T09:03:25","date_gmt":"2021-01-05T14:03:25","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408579"},"modified":"2021-01-05T09:03:25","modified_gmt":"2021-01-05T14:03:25","slug":"geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","title":{"rendered":"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <strong><br \/>\n          <em>GeoVax Also Participating in BIO@JPM During \u201cJ.P. Morgan Week 2021\u201d<\/em><br \/>\n        <\/strong><br \/>\n        \n      <\/p>\n<p>ATLANTA, GA, Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; via <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T4gFzamPSTFOkdwnAdB1F1gxFORFW7BZFZdt4KKO0c9Ms_VmdHLwRheiKO1Sd6S4ZrETOHh4J8kIdwn-5Mayxw3_x6gB7_2dVI42Vt5sgUs=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>NewMediaWire<\/u><\/a> &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L6YP3iZkO-CEklqvknKwuIk11gVloOuMPk-fNheAFPG48MpgDZlRysMy_i26a1-G30v-e2yTKVTQeIeyYjZuYg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">GeoVax Labs, Inc<\/a>. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announced today that Chairman, President and CEO David Dodd will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021.<\/p>\n<p>The presentation will be available for on-demand listening beginning\u00a0at 6:00 AM Eastern Time on Monday, January 11, 2021, through close of business January 14, 2021.\u00a0 For those interested in viewing Mr. Dodd\u2019s presentation, registration can be accessed\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Y7gZfqzSFaYMOH8oLjgXam7UU-Hqw_B2i18_WpVEcXfxn0pQQ0aOMkxq49M7ce1IUF0uwto5CAdz9Mnwk_skCPPBiwY8T80eDT1FG75AEBCm7tQblo554SH5QFbgNxKdSHnMlGQy-hyoIeg988B4twjVKqeB6KXJPpTAE4S0lGgODrl9vR2_2aXqxT6XY_Xc\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a>.<\/p>\n<p>The Company also announced that it will participate in virtual one-on-one meetings with registered biopharmaceutical companies, investors and other interested parties through the one-on-one partnering system hosted by the Biotechnology Innovation Organization (BIO) during the J.P. Morgan conference week January 11-15, 2021. Registration can be accessed\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=E-4eOMryRuxwhoTvDViohAtR0ABMnP3pmPGB88pE1Y8J41nKHYtc86ZTCxKoQPQBAIMn_tVMtgIGLvLBWm2eKxhVWBNXp5fDs0rXkHg901STA4iZK3D-280owPqLVCe-\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a>.<\/p>\n<p>\n        <strong>About GeoVax<\/strong>\n      <\/p>\n<p>GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines against infectious diseases and cancers using a novel patented Modified Vaccinia Ankara-Virus Like Particle (MVA-VLP) based vaccine platform. On this platform, MVA, a large virus capable of carrying multiple vaccine antigens, expresses proteins that assemble into VLP immunogens within (<em>in vivo<\/em>) the person receiving the vaccine. The production of VLPs in the person being vaccinated mimics virus production in a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection. The MVA-VLP derived vaccines elicit durable immune responses in the host similar to a live-attenuated virus, while providing the safety characteristics of a replication-defective vector.\u00a0The goal of the GeoVax technology (GV-MVA-VLP<sup>TM<\/sup>) is to provide high efficacy in a single dose, without the need for additional immune response components (\u201cadjuvants\u201d), strong durability (\u201cminimizing the need for boosters\u201d), the highly-validated safety of MVA, minimal refrigeration requirements, and cost-effective manufacturing.<\/p>\n<p>GeoVax\u2019s current development programs are focused on preventive vaccines against COVID-19, Zika Virus, hemorrhagic fever viruses (Ebola, Lassa, Marburg and Sudan), HIV and malaria, as well as therapeutic vaccines against multiple cancers. The Company has successfully completed six human clinical trials related to HIV, having designed a preventive HIV vaccine candidate to fight against the subtype of HIV prevalent in the geographic markets of the Americas, Western Europe, Japan, and Australia. Human clinical trials for this program are managed by the HIV Vaccine Trials Network (HVTN) with the support of the National Institutes of Health (NIH). GeoVax\u2019s HIV vaccine is also part of two separate collaborative efforts to apply its innovative approach toward a functional cure for HIV, addressing those already infected with HIV.<\/p>\n<p>\n        <strong><br \/>\n          <em>Forward-Looking Statements<\/em><br \/>\n        <\/strong>\n      <\/p>\n<p>\n        <em>This release contains forward-looking statements regarding the timing of the release of GeoVax\u2019s financial results and earnings conference call and the earnings release and call are expected to discuss forward-looking statements regarding GeoVax\u2019s ability to implement its business plan, expected revenues and future success. The words \u201cbelieve,\u201d \u201cmay,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cshould,\u201d \u201cplan,\u201d \u201ccould,\u201d \u201ctarget,\u201d \u201cpotential,\u201d \u201cis likely,\u201d \u201cwill,\u201d \u201cexpect\u201d and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs.\u00a0Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax\u2019s vaccines will be safe for human use, GeoVax\u2019s vaccines will effectively prevent targeted infections in humans, GeoVax\u2019s vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax\u2019s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, the impact of the COVID-19 pandemic continues, and other factors, over which GeoVax has no control.<\/em>\n      <\/p>\n<p>\n        <em>Further information on our risk factors is contained in\u00a0our Quarterly Report on Form 10-Q that we have filed with the SEC.\u00a0Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.<\/em>\n      <\/p>\n<p>GeoVax Labs, Inc.<br \/> 678-384-7220<br \/> investor@geovax.com<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/c1442379-3842-45b3-b393-d5c8884b6d8d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>GeoVax Also Participating in BIO@JPM During \u201cJ.P. Morgan Week 2021\u201d ATLANTA, GA, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announced today that Chairman, President and CEO David Dodd will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation will be available for on-demand listening beginning\u00a0at 6:00 AM Eastern Time on Monday, January 11, 2021, through close of business January 14, 2021.\u00a0 For those interested in viewing Mr. Dodd\u2019s presentation, registration can be accessed\u00a0here. The Company also announced that it will participate in virtual one-on-one meetings with registered biopharmaceutical companies, investors and other interested parties &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408579","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GeoVax Also Participating in BIO@JPM During \u201cJ.P. Morgan Week 2021\u201d ATLANTA, GA, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announced today that Chairman, President and CEO David Dodd will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation will be available for on-demand listening beginning\u00a0at 6:00 AM Eastern Time on Monday, January 11, 2021, through close of business January 14, 2021.\u00a0 For those interested in viewing Mr. Dodd\u2019s presentation, registration can be accessed\u00a0here. The Company also announced that it will participate in virtual one-on-one meetings with registered biopharmaceutical companies, investors and other interested parties &hellip; Continue reading &quot;GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T14:03:25+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference\",\"datePublished\":\"2021-01-05T14:03:25+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"},\"wordCount\":781,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\",\"name\":\"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==\",\"datePublished\":\"2021-01-05T14:03:25+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk","og_description":"GeoVax Also Participating in BIO@JPM During \u201cJ.P. Morgan Week 2021\u201d ATLANTA, GA, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; via NewMediaWire &#8212; GeoVax Labs, Inc. (NasdaqCM: GOVX), a biotechnology company developing vaccines and immunotherapies against infectious diseases and cancers, announced today that Chairman, President and CEO David Dodd will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021. The presentation will be available for on-demand listening beginning\u00a0at 6:00 AM Eastern Time on Monday, January 11, 2021, through close of business January 14, 2021.\u00a0 For those interested in viewing Mr. Dodd\u2019s presentation, registration can be accessed\u00a0here. The Company also announced that it will participate in virtual one-on-one meetings with registered biopharmaceutical companies, investors and other interested parties &hellip; Continue reading \"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T14:03:25+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference","datePublished":"2021-01-05T14:03:25+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/"},"wordCount":781,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/","name":"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==","datePublished":"2021-01-05T14:03:25+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDM1MSMzOTA0MDI3IzUwMDAzMjA1NQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/geovax-to-present-at-the-h-c-wainwright-bioconnect-2021-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GeoVax to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408579","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408579"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408579\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408579"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408579"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408579"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}